Monte Rosa Therapeutics Inc Cash Flow Conversion Efficiency
Monte Rosa Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has a cash flow conversion efficiency ratio of -0.168x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.48 Million) by net assets ($485.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Monte Rosa Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Monte Rosa Therapeutics Inc from 2019 to 2025. This chart illustrates how Monte Rosa Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GLUE live share price for real-time trading data and today's change.
Monte Rosa Therapeutics Inc Cash Flow Conversion Ratio Explained
Monte Rosa Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Monte Rosa Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Monte Rosa Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jupiter Wagons Limited
NSE:JWL
|
-0.041x |
|
CeriBell, Inc
NASDAQ:CBLL
|
-0.100x |
|
GuoChuang Software Co Ltd
SHE:300520
|
0.008x |
|
Time Technoplast Limited
NSE:TIMETECHNO
|
0.065x |
|
Fujian Longxi Bearing Group Co Ltd
SHG:600592
|
0.011x |
|
Ampoc Far-East Co Ltd
TW:2493
|
0.115x |
|
Hunan Corun New Energy Co Ltd
SHG:600478
|
0.004x |
|
Corticeira Amorim
LS:COR
|
0.036x |
Annual Cash Flow Conversion Efficiency for Monte Rosa Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Monte Rosa Therapeutics Inc from 2019 to 2025. Review how much free cash does Monte Rosa Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $233.06 Million | $-22.80 Million | -0.098x | -151.93% |
| 2024-12-31 | $222.94 Million | $42.00 Million | 0.188x | +177.09% |
| 2023-12-31 | $179.25 Million | $-43.80 Million | -0.244x | +28.27% |
| 2022-12-31 | $271.41 Million | $-92.47 Million | -0.341x | -99.44% |
| 2021-12-31 | $347.51 Million | $-59.36 Million | -0.171x | -136.11% |
| 2020-12-31 | $-48.73 Million | $-23.05 Million | 0.473x | -6.90% |
| 2019-12-31 | $-12.15 Million | $-6.17 Million | 0.508x | -- |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more